NanoZymeXNanoZymeX
N

NanoZymeX

Developing a lipid nanoparticle platform for enhanced enzyme replacement therapy.

Active
Advertise here

About

NanoZymeX is a biotech startup spun out of research at the University of Basel. The company is developing a novel platform utilizing lipid nanoparticles to improve enzyme replacement therapies for rare genetic conditions, such as Pompe disease. Their technology aims to enhance the delivery of therapeutic enzymes into target cells and lysosomes, thereby increasing therapeutic activity in affected tissues and reducing immune responses to repeated treatments. The platform is designed to improve existing enzyme therapies and can be adapted to multiple lysosomal storage disorders. NanoZymeX plans to partner with pharmaceutical and biotechnology companies to bring next-generation enzyme therapies to patients.
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does NanoZymeX do?

NanoZymeX is a biotech startup spun out of research at the University of Basel. The company is developing a novel platform utilizing lipid nanoparticles to improve enzyme replacement therapies for rare genetic conditions, such as Pompe disease. Their technology aims to enhance the delivery of therapeutic enzymes into target cells and lysosomes, thereby increasing therapeutic activity in affected tissues and reducing immune responses to repeated treatments. The platform is designed to improve exi…

How much funding has NanoZymeX raised?

NanoZymeX has raised a total of $160K in funding. The most recent round on record is Pre-Seed.

Where is NanoZymeX headquartered?

NanoZymeX is headquartered in Basel, Switzerland.

What industry does NanoZymeX operate in?

NanoZymeX operates in Biotechnology, Rare Diseases, Drug Delivery, Therapeutics.